Pimavanserin adjunctive therapy shows small statistically significant reductions in PANSS scores below clinically meaningful thresholds for schizophrenia

Photo by National Cancer Institute / Unsplash

Asian journal of psychiatry Published June 1, 2026 Medically reviewed June 1, 2026 Study authors: Dos Santos Pereira Samuel Izaias, de Oliveira Isabela Borja, Ferreira Matheus Hissa Lourenço, Mert A… PubMed ↗ DOI ↗ By Dr. Ji-eun Park, MD · Brain, Mind & Pain

Key Takeaway

Note that adjunctive pimavanserin shows small effects below clinically meaningful thresholds for schizophrenia negative symptoms.

This systematic review and meta-analysis examined the efficacy of adjunctive pimavanserin in adults with schizophrenia. The study included 1676 randomized participants and assessed outcomes across various symptom domains and global measures. The certainty of evidence was evaluated with GRADE, and the authors note that clinical evidence remains inconsistent across heterogeneous populations including those with acute exacerbation, inadequate response, and predominant negative symptoms.

Regarding primary outcomes, no clinically meaningful benefit was observed in predominant negative symptom studies. For PANSS total and PANSS negative scores, small statistically significant reductions were observed. However, these effect sizes were well below minimal clinically important difference thresholds. No significant benefits were observed for other symptom domains or global outcomes.

Safety data indicated no increased risk versus placebo for serious adverse events or discontinuations, and the drug was generally well tolerated. Despite the statistically detectable but clinically modest effects, the practice relevance does not support routine clinical use for negative symptoms of schizophrenia.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

PMID42019343

View Original Abstract ↓

Negative symptoms of schizophrenia are a major determinant of functional disability and remain a persistent unmet therapeutic need. Pimavanserin (NbN: serotonin 5-HT₂A receptor inverse agonist/antagonist) has been investigated as an adjunctive treatment for negative symptoms, but clinical evidence remains inconsistent. We conducted a systematic review and meta-analysis to evaluate the efficacy, safety, and tolerability of adjunctive pimavanserin in adults with schizophrenia. PubMed, Web of Science, Cochrane CENTRAL, Scopus, Ovid, Europe PMC, ClinicalTrials.gov, and the WHO ICTRP were searched from inception through August 2025. Randomized controlled trials comparing adjunctive pimavanserin with placebo were included. Random-effects meta-analyses were performed, and treatment effects were interpreted in relation to established minimal clinically important differences (MCIDs). Risk of bias was assessed using Cochrane RoB 2, and certainty of evidence was evaluated with GRADE. Four randomized controlled trials including 1676 randomized participants were identified, encompassing heterogeneous populations (acute exacerbation, inadequate response, and predominant negative symptoms). No clinically meaningful benefit was observed on the primary negative symptom endpoint used in predominant negative symptom studies (NSA-16). Small statistically significant reductions were observed for PANSS total and PANSS negative scores, but effect sizes remained well below MCID thresholds. No significant benefits were observed for other symptom domains or global outcomes. Pimavanserin was generally well tolerated, with no increased risk of serious adverse events or treatment discontinuation versus placebo. Overall, adjunctive pimavanserin demonstrates statistically detectable but clinically modest effects that do not support routine clinical use for negative symptoms of schizophrenia.